Skip to main content
SpringerLink
Log in

News from ASCO

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  • Warsame RM, et al. How costs get discussed (or not) in routine oncology practice. 53rd Annual Meeting of the American Society of Clinical Oncology : abstr. 6512, 2 Jun 2017. Available from: URL: http://abstracts.asco.org/199/AbstView_199_190281.html.

  • Aakhus E, et al. Implementing cost transparency in oncology: A qualitative study of barriers, facilitators, and patient preferences. 53rd Annual Meeting of the American Society of Clinical Oncology : abstr. 6597, 2 Jun 2017. Available from: URL: http://abstracts.asco.org/199/AbstView_199_190098.html.

  • Goldstein DA, et al. A phamacoeconomic analysis of personalized dosing versus fixed dosing of pembrolizumab in first-line PD-L1 positive non-small cell lung cancer. 53rd Annual Meeting of the American Society of Clinical Oncology : abstr. 9013, 2 Jun 2017. Available from: URL: http://abstracts.asco.org/199/AbstView_199_182537.html.

  • Alsaid N, et al. Cost effectiveness of carfilzomib (CAR), ixazomib (IXA), elotuzumab (ELO), or daratumumab (DAR) with lenalidomide and dexamethasone (LEN+DEX) vs LEN+DEX in relapsed/refractory multiple myeloma (R/R MM). 53rd Annual Meeting of the American Society of Clinical Oncology : abstr. 8030, 2 Jun 2017. Available from: URL: http://abstracts.asco.org/199/AbstView_199_190223.html.

  • Carroll K, et al. Cost-effectiveness of nivolumab for treatment of platinum-resistant recurrent or metastatic squamous cell carcinoma of the head and neck. 53rd Annual Meeting of the American Society of Clinical Oncology : abstr. 6026, 2 Jun 2017. Available from: URL: http://abstracts.asco.org/199/AbstView_199_191262.html.

  • The ASCO Post. ASCO 2017: Implementing Cost Transparency in Oncology. Internet Document : 8 Jun 2017. Available from: URL: http://www.ascopost.com/News/55725.

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

News from ASCO. PharmacoEcon Outcomes News 781, 25–26 (2017). https://doi.org/10.1007/s40274-017-4117-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-017-4117-2

Search

Navigation